NVS · Novartis
AI read · Neutral
The AI's read
Higher expected sales for Kesimpta, Scemblix, and Lewvio support growth and reduce risk. But Jefferies says the longer-term picture still depends on products with unanswered questions. Those points do not show a clear change in Novartis's prospects.